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DNA-damaging agents have a long history of use in cancer chemotherapy. The full extent of their cellular
mechanisms, which is essential to balance efficacy and toxicity, is often unclear. In addition, the use of
many anticancer drugs is limited by dose-limiting toxicities as well as the development of drug resistance.
Novel anticancer compounds are continually being developed in the hopes of addressing these limitations;
however, it is essential to be able to evaluate these compounds for their mechanisms of action. This review
covers the current DNA-damaging agents used in the clinic, discusses their limitations, and describes the use
of chemical genomics to uncover new information about the DNA damage response network and to evaluate
novel DNA-damaging compounds.Although considered by some to be a modern disease, cancer in
humans has been documented for millennia (for review, see Da-
vid and Zimmerman, 2010). Currently, cancer accounts for 7 to 8
million deaths (13% of all deaths) worldwide (World Health Orga-
nization, 2012). Despite repeated campaigns to defeat cancer,
such as Nixon’s War on Cancer, all have failed, because cancer
is not a single disease. In fact, it is a collection of highly complex
diseases characterized by unregulated cell proliferation that can
arise from contributions from numerous different factors,
including genetic and environmental.
The treatment of cancer is still largely based on the use of
chemotherapeutic drugs to eliminate cancer cells, reduce tu-
mor growth, and alleviate pain. The first widely used cancer
drugs were discovered in the 1940s as a result of studying vic-
tims of chemical warfare during World Wars I and II (for review,
see Chabner and Roberts, 2005). Soldiers exposed to sulfur
mustard gas were found to have depleted bone marrow and
reduced lymph nodes (Krumbhaar and Krumbhaar, 1919).
Alfred Gilman and Louis Goodman began testing more stable
nitrogen mustard compounds, such as bis and tris b-chlor-
oethyl amines, and found that they caused tumor regressions
in mice with transplanted lymphoid tumors (Gilman, 1963; Gil-
man and Philips, 1946). Next, they treated a patient with late-
stage non-Hodgkin’s lymphoma with tris b-chloroethyl amine
and found that the tumor subsided (Goodman et al., 1946).
Subsequent testing of b-chloroethyl amines in 67 patients
with non-Hodgkin’s lymphoma and leukemia revealed marked
tumor regression (Goodman et al., 1946). It was later noted
that these remissions were short-lived, with resistance to the
compounds developing rapidly; however, the idea that tumors
could be cured, if only temporarily, ushered in an era of wide-
spread research into discovering and characterizing cancer
therapeutics.
Around the same time (1946–1948), Sidney Farber was
studying the effects of folic acid in leukemia patients. He
discovered that, when folic acid was administered to these pa-
tients, it led to increased proliferation of acute lymphoblastic
leukemia cells (Farber, 1949). Folic acid deficiencies were iden-648 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All rightified in patients with megaloblastic anemia, and its administra-
tion was found to stimulate bone marrow maturation and
growth (Wills et al., 1937). Farber’s observation led to collabo-
rations with Yellapragada Subbarao to develop folate analogs
that could chemically block folic acid and hence inhibit the pro-
duction of abnormal bone marrow associated with leukemia.
This was one of the first examples of rational drug design, as
opposed to serendipitous discovery. One of these folate ana-
logs, aminopterin, was administered to children with acute
lymphoblastic leukemia and led to successful remissions
(Farber and Diamond, 1948). Though the remissions were brief,
it was clear that antifolates had potential as anticancer com-
pounds. Another folate analog with less toxicity than aminop-
terin, methotrexate (amethopterin) was one of the first drugs
to cure a solid tumor (choriocarcinoma) in the 1950s (Li et al.,
1958).
It took a decade to identify what these two compounds
had in common: both nitrogen mustards and folate anta-
gonists are effective at killing cancer cells due to their DNA-
damaging properties. DNA integrity is critical for proper cellular
function and proliferation. High levels of damage to DNA are
detected by cell-cycle checkpoint proteins, whose activation
induces cell-cycle arrest to prevent the transmission of
damaged DNA during mitosis. DNA lesions that occur during
the S phase of the cell cycle block replication fork progression
and can lead to replication-associated DNA double-strand
breaks (DSBs), which are among the most toxic of all DNA le-
sions. If the damaged DNA cannot be properly repaired, cell
death may result. Cancer cells typically have relaxed DNA
damage-sensing/repair capabilities and, more importantly,
they are capable of ignoring cell-cycle checkpoints, allowing
the cells to achieve high proliferation rates; this also makes
them more susceptible to DNA damage, since replicating
damaged DNA increases the likelihood of cell death. The
concept of aiming at DNA as a target for anticancer drugs
inspired the development of numerous anticancer compounds,
such as cisplatin, doxorubicin, 5-fluorouracil, etoposide, and
gemcitabine.ts reserved
Table 1. Properties of DNA-Damaging Compounds Used in the Treatment of Cancer
Drug Mode of Action Major Side Effects Mechanisms of Resistance
Cisplatin DNA crosslinker nephrotoxicity; neurotoxicity;
ototoxicity
decreased uptake; increased efflux; enhanced
replication bypass; increased DNA repair capacity;
increased DNA damage tolerance; failure of death
pathways
Carboplatin DNA crosslinker myelosuppression
Oxaliplatin DNA crosslinker neurotoxicity; pulmonary toxicity;
hepatotoxicity






increased DHFR expression; mutations in folate
transporter genes
Doxorubicin topoisomerase II poison cardiotoxicity; myelosuppression;
neurotoxicity
P-glycoprotein-mediated MDR; decreased
topoisomerase II expression; enhanced DNA
repair; decreased activity due to increased
glutathione levels
Daunorubicin topoisomerase II poison cardiotoxicity; myelosuppression
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In the 1960s and 1970s, there was a surge of interest in devel-
oping anticancer compounds that react chemically with DNA.
These included compounds that directly modify DNA bases,
intercalate between bases, or form crosslinks in DNA. The nitro-
gen mustards studied by Goodman and Gilman act by directly
alkylating DNA on purine bases, leading to stalled replication
fork progression and subsequent cell death via apoptosis. Deriv-
atives of nitrogen mustards were developed, including the DNA
alkylators cyclophosphamide, chlorambucil, and melphalan, all
of which are currently used in clinical therapeutics. Other exam-
ples of DNA-alkylating agents used in cancer treatment include
nitrosoureas (e.g., carmustine, lomustine, and semustine) and
triazenes (e.g., dacarbazine and temozolomide). Natural prod-
ucts which alkylate DNA bases were also discovered around
this time, such as mitomycin C and streptozotocin. These com-
pounds and several of the alkylators mentioned above crosslink
DNA on opposite strands of the double helix (interstrand cross-
links), resulting in a more potent effect against cancer cells
compared to monofunctional alkylation. For example, carmus-
tine (N,N0-bis(2-chloroethyl)-nitrosourea) binds to the N1 of
guanine on one DNA strand and the N3 of cytosine of the
opposite strand to form interstrand crosslinks, which block
DNA replication and can cause cell death if not repaired (Fisch-
haber et al., 1999).
The discovery of the alkylating-like platinum agents had a
significant positive impact on anticancer drug research. Cis-dia-
mminedichloroplatinum(II) (cisplatin), was discovered by acci-
dent in the 1960s, when a magnetic field generated by platinum
electrodes was shown to block E. coli cell division (Rosenberg
et al., 1965; Table 1). Cisplatin, as its name implies, contains a
platinum core with two chloride leaving groups and two amine
nonleaving groups (Figure 1). After cell entry, aquation of the
chloride groups allows the platinum to bind guanine residues
and, to a lesser extent, adenine residues to form adducts on
DNA. When two platinum adducts form on adjacent bases on
the same DNA strand, they form intrastrand crosslinks (Kelland,
2007; Siddik, 2003). The structures of these platinum-DNA ad-
ducts have been solved at atomic resolution using X-ray crystal-
lography and nuclear magnetic resonance (Huang et al., 1995;
Takahara et al., 1995). Inspired by the efficacy of cisplatin, plat-Chemistry & Binum-based analogs have been developed, including carbopla-
tin and oxaliplatin, which also act by forming DNA crosslinks
but have different pharmacological properties, decreased side
effects, and increased efficacy against different tumors (Wheate
et al., 2010; Table 1). In particular, platinum compounds have
been very successful in the treatment of solid tumors. Indeed,
cisplatin therapy can cure over 90%of all testicular cancer cases
and also has good efficacy in the treatment of ovarian, bladder,
head and neck, and cervical cancers (Kelland, 2007). Current ef-
forts to develop cisplatin analogs are aimed at reducing toxicity
to nontargeted tissues, which results in dose-limiting toxicities,
such as nephrotoxicity and neurotoxicity. The spectrum of
different platinum compounds under development is broad,
and platinum compounds have also encouraged the synthesis
and testing of other metal-containing compounds for use in
chemotherapy (Bruijnincx and Sadler, 2008; Ko¨pf-Maier, 1994).
Antimetabolites
Antimetabolites represent a class of anticancer drugs that mimic
normal cellular molecules and consequently interfere with DNA
replication. Many of these compounds are DNA antagonists
that exert their activity by blocking nucleotide metabolism path-
ways. Examples of widely used antimetabolite anticancer com-
pounds include the pyrimidine analogs 5-fluorouracil (5-FU),
capecitabine, floxuridine, and gemcitabine, and the purine ana-
logs 6-mercaptopurine, 8-azaguanine, fludarabine, and cladri-
bine. The incorporation of purine and pyrimidine analogs into
DNA during the S phase of the cell cycle prevents proper nucle-
obase addition, causing DNA replication to fail. For example,
5-FU can be incorporated into DNA and RNA in place of thymine
or uracil, respectively. Because 5-FU contains a fluoride atom at
the 5-carbon position on the ring, it prevents the addition of the
next nucleobase on the strand, therefore terminating chain elon-
gation, which induces apoptosis (Parker and Cheng, 1990). In
addition to nucleobase analogs, other antimetabolites inhibit en-
zymes important for DNA synthesis. Methotrexate, aminopterin,
and newer antifolates, such as pemetrexed, inhibit the dihydro-
folate reductase enzyme to block the synthesis of nucleotides.
Another antifolate, ralitrexed, directly inhibits thymidylate syn-
thase. Methotrexate, the primary antifolate used in chemo-
therapy, displays a broad range of antitumor activities againstiology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 649
Figure 1. Structures of Selected DNA-
Damaging Anticancer Compounds
Cisplatin, carboplatin, oxaliplatin, and picoplatin
are platinum-based compounds. Doxorubicin and
daunorubicin are anthracyclines.
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and Cronstein, 2000; Table 1).
Topoisomerase Poisons
Amechanistically distinct way to interfere with normal DNA func-
tion is to target protein-DNA complexes. The assembly of pro-
teins onto DNA is crucial for many DNA processes, including
transcription, replication, recombination, and repair. Therefore,
it is not surprising that many DNA-active drugs act by interfering
with DNA-protein binding. Topoisomerases are a class of en-
zymes responsible for releasing the torsional strain of the DNA
double helix. Topoisomerase I allows the passage of a single
DNA strand through a transient single-strand break created in
the complementary strand of the double helix. Topoisomerase
II cuts both strands of the double helix to allow the passage of
an intact helix to unwind supercoiled DNA. Topoisomerase poi-
sons trap the DNA-enzyme intermediate as a complex, prevent-
ing religation of the break, inhibiting replication fork progression,
and causing toxic DSBs (for review, see Froelich-Ammon and
Osheroff, 1995). Initial insights into how these inhibitors work
came from plant analogs developed from podophyllotoxin and
its derivatives, such as etoposide and teniposide, which were
found to have antineoplastic effects. Interestingly, it was found650 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reservedthat DNA strand breaks caused by etopo-
side did not form when etoposide was
incubated with purified DNA (Wozniak
and Ross, 1983). It was soon discovered
that etoposide binds to the topoisomer-
ase II-DNA complex (Chen et al., 1984).
The cellular levels of topoisomerase II
determine the efficacy of etoposide as a
cytotoxic agent, with higher levels leading
to greater efficacy (Burgess et al., 2008).
This correlation can be used to inform
and design topoisomerase II-mediated
chemotherapy. Another plant-produced
product, camptothecin, was found to be
a topoisomerase I poison (Hsiang et al.,
1985). As with etoposide, camptothecin
does not bind the enzyme or DNA alone
but rather binds to the DNA-topoisomer-
ase complex to inhibit strand religation
(Hertzberg et al., 1989).
The anthracycline antibiotics are a
group of antineoplastic agents that, like
etoposide, poison topoisomerase II, but
they have additional antitumor mecha-
nisms, including the ability to intercalate
into DNA (Cutts et al., 2005; Table 1).
The anthracyclines doxorubicin and
daunorubicin (Figure 1) (derived from
Streptomyces peucetius) are widelyused to treat breast cancer, small-cell lung tumors, soft tissue
sarcomas and lymphomas, and acute lymphoblastic or myelo-
blastic leukemias (Minotti et al., 2004). These compounds and
the newer anthracyclines epirubicin and idarubicin have become
mainstays of cancer chemotherapy. Anthracyclines can be
extremely cytotoxic, likely owing to their multiple mechanisms
of action in addition to binding the DNA-topoisomerase com-
plex. Anthracyclines are also able to intercalate into DNA,
generate free radicals, bind and alkylate DNA, crosslink DNA,
interfere with helicase activity, and induce apoptosis (for review,
see Minotti et al., 2004). Among their more significant toxic side
effects is their well-documented cardiotoxicity (for review, see
Olson and Mushlin, 1990).
Limitations of Current Chemotherapeutics
In describing the limitations of anticancer treatments, we will
focus on two of the most successful antineoplastic compounds,
cisplatin and doxorubicin, as exemplar agents.
A primary cause of failure of anticancer treatments is the
intrinsic or acquired resistance of a tumor to the drug, which
often leads to disease reoccurrence (Sawicka et al., 2004).
This was initially characterized in the early studies of the nitrogen
mustards: after tumors receded, they would recur and
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to anticancer compounds can arise in various ways, and under-
standing these mechanisms can help inform new strategies of
cancer treatment. In many cases, cells manifest multidrug resis-
tance by reducing drug uptake and/or increasing drug efflux
through modulation of the expression or activity of drug pumps,
such as P-glycoprotein and other multidrug resistance (MDR)
transporters in the ATP-binding cassette family (Gottesman,
2002). In cases where the drug has a specific target, such as
with the antifolates, loss of a cell surface receptor or mutation
of the specific drug target (e.g., by gene amplification in the
case of dihydrofolate reductase) can cause resistance. Resis-
tance to the anticancer drug cisplatin can occur as a result of
increased levels of drug detoxification by boosting of the pro-
duction of cellular thiols, enhanced replication bypass of plat-
inum-DNA adducts, changes in levels of regulatory proteins,
increased DNA repair capacity, increased DNA damage toler-
ance, and the failure of cell death pathways (Wang and Lippard,
2005). Doxorubicin resistance can arise from alterations in DNA
damage-sensing and repair capacities and can also arise from
decreased topoisomerase II expression and/or catalytic activity.
Increased expression of antioxidants that increase glutathione
peroxidase activity also decreases doxorubicin efficacy
(Sawicka et al., 2004). Specific drug resistance can, in some
cases, be addressed by combination treatments with com-
pounds that act through different mechanisms of action.
Another limitation in the use of anticancer compounds arises
from adverse toxicity to nontargeted tissues. Becausemost anti-
cancer drugs were discovered based on their efficacy against
cancer cells, little attention was initially given to their effects on
other tissues. One major side effect of cisplatin is nephrotoxicity
(Yao et al., 2007). Although the proximal tubule cells of the kidney
are quiescent, they are selectively damaged by cisplatin. Mech-
anisms that have been suggested to explain toxicity to these
cells include activation of mitogen-activated protein kinases,
reactive oxygen species, and stimulation of inflammation and fi-
brogenesis (Yao et al., 2007). Another significant dose-limiting
side effect of cisplatin is toxicity to the brain, where cisplatin
use can lead to tinnitus, high-frequency hearing loss, and
peripheral neuropathies, including loss of vibration sense, pares-
thesia, and weakness (Wang and Lippard, 2005). Platinum-
based compounds preferentially enter the dorsal root ganglia
and peripheral nerves and do not readily penetrate the blood-
brain barrier (BBB). Cisplatin will bind to DNA and form adducts
in dorsal root ganglia neurons, leading to apoptosis of the
neurons. The mechanism by which the platinum-DNA adducts
lead to neuronal apoptosis is not fully understood. Interestingly,
because of their inability to traverse the BBB, platinum-based
compounds can be delivered directly to the central nervous
system to treat brain tumors (Olivi et al., 1993).
The main limitation to doxorubicin use is cardiotoxicity,
including cardiomyopathy and congestive heart failure (CHF)
(Minotti et al., 2004; Olson and Mushlin, 1990). Swain et al.
(2003) analyzed 630 patients with breast carcinoma or small-
cell lung carcinoma and found that 26% of patients experi-
enced doxorubicin-related CHF at a dose of 550 mg/m2. Several
mechanisms have been proposed to explain the particular sensi-
tivity of the heart to doxorubicin-mediated toxicity. A widely
accepted explanation is that oxidative stress induced by intra-Chemistry & Bmyocardial production of reactive oxygen species following
doxorubicin treatment produces cardiotoxic effects (Simunek
et al., 2009). Another is that the heart is susceptible to the anthra-
cyclines, owing to its elevated levels of mitochondria activity,
because doxorubicin binds to cardiolipin within the mitochon-
drial inner membrane (Berthiaume and Wallace, 2007). Addi-
tional explanations for doxorubicin toxicity include inhibition of
nucleic acid and protein synthesis, release of vasoactive amines,
alterations in adrenergic function and adenylate cyclase activity,
changes in calcium transport, and alterations in cellular iron
metabolism (Carvalho et al., 2009). Another organ targeted by
doxorubicin is the brain, despite the drug not being able to cross
the blood brain barrier. Studies have suggested that tumor ne-
crosis factor-a (TNF-a) is responsible for this toxicity (Tangpong
et al., 2006). Doxorubicin increases the production of TNF-a,
which in turn increases the production of inflammatory cytokines
bymicroglial cells in the brain. Drug-induced oxidative stress has
also been linked to doxorubicin-mediated toxicity of the liver
(Kalender et al., 2005).
While the mechanisms that underlie these side effects have
been studied for years, our understanding remains incomplete.
The severity of these side effects can be reduced by using com-
bination therapies that have the effect of minimizing the overall
dose of each single agent. In addition, synergistic combinations
with nonoverlapping toxicities can reduce side effects. Timing of
combinations can also be exploited; for example, patients
undergoing doxorubicin therapy are often pretreated with
tamoxifen to reduce the level of toxic metabolites derived from
doxorubicin (Sawicka et al., 2004). While these and other clinical
strategies can certainly improve outcomes, new therapies and a
better understanding of traditional therapies will be invaluable.
New Designs for Chemotherapeutics
A common theme in drug discovery and development is to
address limitations in current anticancer therapies by designing
novel compounds with mechanisms that are based on success-
ful drugs. Thousands of cisplatin analogs have been synthesized
with the goals of (1) reducing toxicity to patients, (2) overcoming
tumor resistance, and (3) increasing the range of antitumor activ-
ity. Early work in the design of novel platinum-based anticancer
drugs focused on developing compounds through the modifica-
tion of substituents surrounding the cisplatin core (Hambley,
1997; Figure 1). An early, clinically successful cisplatin analog,
carboplatin, was developed by replacing the chloride leaving
groups with a more stable bidentate dicarboxylate ligand
(Figure 1). Carboplatin treatment is less nephrotoxic and less
neurotoxic; however, it can lead to myelosuppression (Kelland,
2007). It also requires a higher dosage for efficacy compared
to cisplatin. Another cisplatin analog, oxaliplatin, contains a dia-
minocyclohexane carrier as the nonleaving group. Oxaliplatin
was shown to exhibit a different pattern of sensitivity against
the National Cancer Institute-60 panel of tumor cell lines, which
may be related to its ability to form crosslink patterns distinct
from cisplatin (Rixe et al., 1996). Interestingly, oxaliplatin damage
does not induce expression of genes involved inmismatch repair
(Raymond et al., 2002). Picoplatin was designed to increase the
steric bulk around the platinum core in an effort to reduce thiol-
mediated inactivation. Picoplatin was found to have activity in
cells resistant to cisplatin and to have antitumor activity in vivoiology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 651
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endpoint of overall survival in Phase III trials for cisplatin-resis-
tant small-cell lung cancer, it is currently in Phase II trials for met-
astatic colorectal cancer (Ciuleanu et al., 2010).
While these approaches have led to several compounds
currently in clinical trials, because of their structural similarities
to currently used platinum drugs, it is more likely that these com-
pounds will offer incremental versus radical improvements over
existing drugs. Approaches to platinum-based compound
design that address the issue of drug resistance by maintaining
antitumor activity but that are not constrained to adhering to all of
the structure-activity features of cisplatin and its analogs, have
significant potential. The design of compounds with biologically
active carrier ligands has paved theway for platinum-intercalator
complexes, in which the carrier group functions independent of
the platinum. To date, compounds have been generated in which
cisplatin is attached to DNA-intercalators, such as acridine or-
ange, chloroquine, and ethidium bromide, essentially bringing
the platinum to its site of action (Baruah et al., 2004). In addition
to DNA-intercalators, ‘‘hybrid drugs,’’ in which the platinummoi-
ety is attached to doxorubicin or to estrogen analogs, have been
tested and found to have increased efficacy against cisplatin-
resistant tumors (Gagnon et al., 2004; Zunino et al., 1986).
The fact that cancer chemotherapy is limited by drug toxicity
and resistance highlights the need to better understand drug
mode of action within the cell. In addition, there is a clear need
for novel compounds that act through different and/or comple-
mentary mechanisms, which can be combined with existing
agents to overcome resistance. These novel compounds also
need to be evaluated to understand their mechanisms of action.
Unbiased methods to examine drug function can lead to the
development of better anticancer drugs and treatment regimens.
Below, we describe recent efforts and important insights that
have come from such approaches.
Chemical Genomic Screening to Understand Drug
Mechanism of Action
Since the completion of the human genome sequence in 2003,
we have amassed a wealth of structural and functional informa-
tion about the human genome and proteome. Until quite
recently, much of this information had not been utilized in the
development of new therapies. This is now changing, with recent
advances in molecular biology, genetic engineering, and
genome-scale screening providing powerful new technologies
for identifying drug targets and understanding drug mechanism
of action. Within the human genome, it is estimated that approx-
imately 3,000 human genes are ‘‘druggable,’’ defined by the po-
tential ability of their protein products to bind drug-like chemical
entities (Hopkins and Groom, 2002). However, less than half of
the proteins expressed by the human genome are functionally
characterized, suggesting that this number is an underestimate.
Furthermore, this characterization is a starting point; it is also
possible that the number of potential targets could be larger
than the number of genes in the genome, for example, posttrans-
lationally modified proteins or splice variants may be specifically
druggable. To compile a comprehensive understanding of a
drug’s cellular actions, it would be ideal to identify all primary
and secondary targets of a drug. To this end, tools need to be
developed that are rapid, cost-efficient, and can be used to652 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righstudy all cellular proteins (and other macromolecules) with
different types of small molecule drugs or probes. Chemical ge-
nomics is one such approach, which employs small molecules to
explore gene function and to identify potential drug targets. An
early example of the power of chemical genetics was the charac-
terization of the protein tubulin as ‘‘colchicine-binding protein’’;
this discovery was made a decade before the tubulin gene was
sequenced and 50 years before the term ‘‘chemical biology’’
was coined (Taylor, 1965). The complete sequence of the
genome of human as well as other organisms has provided an
invaluable ‘‘parts list’’ of potential targets. Below, we describe
several comprehensive screening approaches to use that gene
list to guide drug discovery.
Chemical Genomic Screens in Yeast
The budding yeast Saccharomyces cerevisiae has been the
benchmark organism for the development, testing, and
application of genomic technologies. It is also an ideal model
organism for the development of high-throughput genomic
screens. The first eukaryote to have its genome sequence
completed, S. cerevisiae has a well-characterized genome and
proteome, a rapid generation time, is inexpensive to cultivate,
and is highly amenable to genetic manipulations, such as gene
deletion and dosage level variation (Botstein et al., 1997). A great
resource for the development of systematic screening technol-
ogy in S. cerevisiae is the yeast knockout collection (YKO).
This is a complete deletion set of haploid strains and heterozy-
gous and homozygous diploid strains, in which each open
reading frame in the yeast genome has been precisely deleted
from start to stop codon and replaced with a kanMX-dominant
drug resistance cassette (Giaever et al., 2002; Winzeler et al.,
1999). The cassette contains two unique 20-nucleotide se-
quences, which act as barcodes for identifying each deletion
strain. These barcodes are flanked by common primer se-
quences, allowing for PCR amplification of barcodes and subse-
quent hybridization to a DNA barcode microarray (Pierce et al.,
2006) or next-generation sequencing (Smith et al., 2009) to iden-
tify strains in a mixed population of deletion strains. Therefore,
the YKO collection can be pooled and grown in parallel
and the relative abundance of each strain can be determined
by the abundance of each barcode.
Indeed, the YKO collection presents an ideal resource for
competitive growth assays that allow the systematic evaluation
of growth of the deletion mutants in different conditions. By
growing the strains in the presence of drug, one can identify
strains that confer growth advantages or disadvantages to the
drug (Figure 2). This pooled approach allows for a rapid method
of identifying growth effects using an unbiased, miniaturized
approach (Hoon et al., 2008).
One of the first chemical genomic screens developed using
the YKO collection is based on the concept of haploinsufficiency,
where a diploid cell bearing one single copy of a given gene
grows indistinguishably from wild-type, except in conditions
that require full protein function or activity. The assay, known
as drug-induced haploinsufficiency profiling (HIP) is based on
the observation that a strain containing a heterozygous deletion
in an essential gene encoding the drug target results in sensitiza-
tion of that strain to the drug (Giaever et al., 1999, 2004; Lum
et al., 2004). Therefore, in a pooled culture, that strain wouldts reserved
Figure 2. Chemical Genomic Screens
(A) The HIPHOP assay in yeast. (1) The YKO collection is pooled and (2) grown in the presence of a compound. (3) Genomic DNA is extracted from the pool and (4)
DNA barcodes are PCR amplified. (5) The barcodes are hybridized to an Affymetrix TAG4 microarray. The signal intensity from the microarray is compared to an
untreated control, and the relative intensity represents relative abundance of the strain in the pool.
(B) An shRNA-based loss-of-function screen. (1) A pooled shRNA library is (2) packaged into retro- or lentiviruses. (3) The virus pool is used to infect cultured cells,
which are (4) grown in the presence of drug. (5) Genomic DNA is then extracted from the cells, and (6) hairpin sequences are amplified by PCR and/or digested to
produce half-hairpin barcodes. (7) The barcodes are hybridized to a DNA microarray, and the signal intensity obtained on each probe is analyzed to find the
relative abundance (compared to a no-drug control) of each shRNA in the population.
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the ability to identify direct targets of compounds and proteins
that may act in the same pathway as the target. In numerous
studies, this assay has proven its ability to identify targets ofChemistry & Bwell-known and novel compounds (Hillenmeyer et al., 2008;
Smith et al., 2009; St Onge et al., 2007). For example, Giaever
et al. (2004) demonstrated the power of the HIP assay for drug
target identification through screens of ten diverse compounds,iology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 653
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methotrexate-sensitive mutants, the most highly sensitive strain
was that containing a heterozygous deletion for the yeast dihy-
drofolate reductase gene, DFR1. The HIP screen is also able to
uncover additional pathways, through which some compounds
act. The antimetabolite anticancer agent 5-FU is known to act
through inhibition of thymidylate synthase. In HIP screens of
this compound, genes that confer sensitivity were those involved
in ribosome biogenesis and ribosomal RNA (rRNA) processing
(Giaever et al., 2004; Lum et al., 2004), an observation that
was subsequently confirmed in follow-up studies showing
that 5-FU blocks rRNA processing by the exosome (Lum et al.,
2004).
Homozygous profiling (HOP) is similar to HIP but instead uses
complete homozygous deletions to identify genes that confer
resistance to a drug. This assay can be used to identify direct
targets, as demonstrated by its ability to identify FKBP12 and
TOR as targets of rapamycin (Heitman et al., 1991). In many
cases, this assay is used to identify genes in pathways that buffer
the effects of the compound. The HOP assay is useful in studies
where there is no specific protein target or where the target is
known and identification of genes that interact with the target
is required. An important application of HOP is to identify resis-
tance genes in pathways that may be functionally redundant or
have high transcriptional compensation in the cell, and has
been particularly powerful for identifying genes that are involved
in the DNA damage response (DDR) (Birrell et al., 2001; Chang
et al., 2002; Workman et al., 2006).
Examples of the use of HOP to study DDR include a study
by Birrell et al. (2001), where the assay was used to identify
genes involved in UV radiation sensitivity. The authors were
able to identify genes known to be involved in DNA repair path-
ways, such as nucleotide excision repair, cell-cycle checkpoints,
homologous recombination, and postreplication repair. This
study led to the identification of three genes (THR1, LSM1, and
YAF9) not previously known to be involved in DNA damage repair
pathways. Two of these genes have human orthologs associated
with cancer. Lee et al. (2005) used the HOP assay to identify
genes required for resistance to DNA-damaging agents with
diverse mechanisms of action. In this study, 12 compounds
that damage DNA were tested to uncover genes involved in
distinct DDR modules that are important to repair damage by
each compound. The authors found that relative importance
of different DDR modules was able to distinguish between
compound mechanisms. Specifically, they identified genetic de-
terminants required for resistance against DNA interstrand
crosslinking agents. In addition, genes that were previously un-
linked to DDR pathways were found in this study.
The recent availability of a genome-wide haploid deletion
mutant library in the fission yeast Schizosaccharomyces pombe
has made chemical genomic screens possible in this distantly
related yeast (Kim et al., 2010). Several groups have screened
this library against DNA-damaging agents to uncover genes in
the S. pombe DDR and to assign functions to uncharacterized
genes (Deshpande et al., 2009; Pan et al., 2012). S. pombe
diverged from S. cerevisiae up to 1,000 million years ago, and
each species shares homologs with metazoans that the other
lacks (Forsburg, 2005); therefore, comparative chemical
genomic screens in both organisms can be used to better char-654 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righacterize compound mechanism of action and to inform human
studies. Kapitzky et al. (2010) developed a cross-species
screening platform to study compounds of known and unknown
function, including several DNA-damaging agents. The study re-
vealed that cross-species profiling is a more ideal predictor of
drug mode of action than single-organism profiling and used
their approach to identify an uncharacterized compound, NSC-
207895, as a DNA-damaging agent. A recent study by our lab
used a similar comparative chemogenomics approach by
performing HOP assays in S. cerevisiae and S. pombe to eval-
uate the potential of 11 platinum-acridine hybrid compounds
as anticancer agents (Cheung-Ong et al., 2012). Four platinum-
acridine agents elicited responses from DDR genes; interest-
ingly, their mechanisms of action were found to be distinct
from the DNA-crosslinking produced by the classical platinum
agent cisplatin. The characterization of novel compounds as
DNA-damaging agents is of considerable interest for clinical
development.
Systematic Screens to Characterize Genetic Responses
to DNA Damage
Yeast strains that contain pairs of gene deletions have been
extremely useful for studying genetic interactions, also known
as epistasis (Costanzo et al., 2010). Taking this concept a step
further, perturbing the double mutants (e.g., with drug applica-
tion) can uncover changes in genetic interactions or novel func-
tional relationships in response to a compound. St Onge et al.
(2007) examined genetic interactions between 26 genes whose
single deletion mutants conferred resistance to the DNA-alkylat-
ing agent methyl methanesulfonate (MMS) in previous HOP
assays (Giaever et al., 2002; Lee et al., 2005). The fitness of
650 doublemutant strainswas examined in pooled liquid culture,
similar to the assays described above, to identify alleviating and
aggravating interactions. The authors use the resulting interac-
tion network to predict roles for DDR genes, such as a role for
Mph1 helicase in resolving recombination-derived DNA interme-
diates.
Bandyopadhyay et al. (2010) adapted the drug-treated double
mutant approach to a colony-based readout, which they called
differential epistatic miniarray profiling, which, similar to the
St. Onge et al. study, quantifies genetic interactions between
pairs of genes and compares the results of two different treat-
ments. Genetic interactions between 418 yeast genes involved
in signaling, transcription, and DNA repair were interrogated by
generating 80,000 double mutant strains. These strains were
grown in the presence or absence of the MMS on solid media
and their colony sizes evaluated. The resulting differential
epistatic network was highly enriched for DDR genes. Several
genes in DNA repair pathways acted as ‘‘hubs’’ for interactions
of many known DDR genes. This observation led to the predic-
tion that hub genes previously unlinked to DDR, such as SLT1
and CBF1, could be involved in DDR or related processes.
Indeed, Cbf1 was found to be required for cell-cycle checkpoint
activation and induction of the DNA damage-indicating histone
modification gH2AX. These two studies highlight the utility of
combinatorial deletion profiling to study changes in genetic net-
works in response to DNA damage. The results of these screens
may prove important for studies of cancer genetics, since DDR
pathways are frequently mutated in cancer cells.ts reserved
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PerspectiveAnother yeast strain collection that has been useful to study
cellular responses to DNA-damaging agents is the genome-
wide collection of GFP-tagged proteins. Tkach et al. (2012) intro-
duced DNA damage to this collection by addition of MMS or
hydroxyurea (HU) and examined global changes in protein levels
and localization. Following compound treatment, the authors
identified 356 proteins that changed in abundance and 254
that changed in localization with little overlap; enrichment anal-
ysis of these proteins indicated that the biological processes
differed between these classes. Within the protein localization
class, there was significant overlap in localization changes and
destination in HU and MMS. Further analysis revealed that
proteins that shared the same localization after compound treat-
ment indicated a common biological function. The authors iden-
tified an additional class of DDR proteins, including Cmr1, Hos2,
Apj1, and Pph21, that form nuclear foci away from the well-char-
acterized DNA double-strand break foci. This study uncovered
previously unknown DNA damage response pathways that allow
a better understanding of this important cellular pathway and can
allow the identification of genes involved in cancer pathways.
Chemical Screens in Multicellular Organisms
Screening compounds in whole organisms is advantageous
compared to single-celled organism and cultured cell screens,
because, in addition to providing a greater array of phenotypic
readouts, it allows for the evaluation of compound toxicity, tissue
specificity, and drug bioavailability. To provide a rapid method
for evaluating chemical libraries, these model organisms should
be amenable to geneticmanipulation, and appropriate screening
platforms would be required for large-scale screening of com-
pounds. In vivo screening of anticancer compounds allows the
selection of compounds that specifically act against tumor cells
without adverse toxicity to the host; this approach can be used to
identify new anticancer compounds that address the limitations
of current therapeutics.
The fruit fly Drosophila melanogaster shares many cancer-
relevant pathways with humans and can be used to model tumor
growth and to evaluate anticancer compounds (for review, see
Gladstone and Su, 2011). Two notable studies use cancer
models developed in D. melanogaster to examine the effects
of anticancer compounds in whole animal screens. Willoughby
et al. (2013) developed a platform for high-throughput screening
of diverse chemical compounds and applied the screens to
identify inhibitors of tumor formation in a D. melanogaster Ras-
driven cancer model. Evaluation of 2,000 compounds uncovered
the glutamine analog acivicin as an inhibitor of tumor growth and
identified CTP synthase as a potential target of acivicin. Dar et al.
(2012) used a Ret-driven model of multiple endocrine neoplasias
and demonstrated that in vivo screening and genetic analysis
could identify pathways that allow for increased efficacy and
reduced toxicity of known compounds. The information gath-
ered in their study may prove extremely important for the design
of novel anticancer compounds and/or the development of com-
bination therapies to specifically target genes in these pathways.
The zebrafish Danio rerio is well-suited for whole organism
screens, because it is evolutionarily closer to humans than
Drosophila and growth can be readily monitored due to their
transparent embryos and discrete organs. D. rerio has become
a valuable vertebrate model system for modeling cancers (forChemistry & Breview, see Huang et al., 2011). Yeh et al. (2008) employed a
transgenic model for acute myelogenous leukemia (AML1-
ETO) that mimics cell differentiation defects that occur in human
AML. A library of 2,000 compounds was screened against these
transgenic zebrafish and a cyclooxygenase 2 inhibitor was found
to reverse the downstream effects of the transgene. This discov-
ery could lead to enhanced therapeutic potential in combination
with antiproliferative drugs for the treatment of AML. Xiang et al.
(2009) used a combinatorial chemistry approach to identify tu-
mor cell growth inhibitors that act via cyclin-dependent kinases
(CDKs), which are cell-cycle proteins that have abnormal activity
in human tumors. CDK inhibitors were designed, synthesized,
and rapidly screened against whole zebrafish embryos. A lead
compound with selective inhibition of CDK2 function was
discovered that also exhibits efficacy in human cells. The combi-
nation of synthetic chemistry and whole organism screening
provides a streamlined method for the rapid development of
target-specific compounds.
Functional Genomics in Mammalian Cells
Model organism research has demonstrated the importance of
employing genomics and chemical genomics to understand bio-
logical function and human disease. However, although model
organisms are excellent test beds for understanding well-
conserved processes, there are processes that can only be
studied in genetically related cell types. Indeed, adapting loss-
of-function and gain-of-function screens performed in model or-
ganisms to mammalian systems has long been a goal, and
recently, great strides have been made toward this goal. Per-
forming genomic studies in mammalian systems is more chal-
lenging on several fronts: genetic manipulation, while improving
dramatically, is still difficult, and these screens are cost and labor
intensive.
RNA interference is the process by which noncoding double-
stranded RNA (dsRNA) molecules mediate target-specific degra-
dation of messenger RNA (mRNA). Observed in C. elegans when
antisense RNA molecules were tested for their ability to inhibit
gene expression (Fire et al., 1998), Fire and Mello found that
dsRNA was more potent in triggering gene silencing than single-
stranded RNA; this work was recognized with a Nobel Prize in
2006 (for a review of RNA interference [RNAi], see Hannon,
2002). The ease of genetic manipulation through RNAi has pro-
duced a paradigm shift in mammalianmolecular biology research
by accelerating the development of genome-scale functional
studies in human cells. RNAi-based loss-of-function studies now
allowone to examine human genes directly in cultured cells, either
individually or in pooled assays. Both commercial and academic
laboratories have generated a number of large genome-scale
short interfering RNA (siRNA), short hairpin RNA (shRNA), and en-
doribonuclease-prepared siRNA (esiRNA) libraries in plasmids
and viral vectors that enable large-format screening of human
genes.To illustrate thediversityof these resources,TheRNAiCon-
sortium has a library of 90,000 shRNA constructs that target
18,000 human genes in lentiviral vectors (Moffat et al., 2006),
the Netherlands Cancer Institute has a library of 24,000 19-mer
shRNAs in retroviral vectors (Bernards et al., 2006), and the Han-
non and Elledge labs generated a library of microRNA-adapted
shRNAs (shRNA-miRs), which contains 395,830 shRNA-miRs
against 57,293 human transcripts (Olson et al., 2006).iology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 655
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are that RNAi molecules can be easily introduced, either tran-
siently (siRNA and esiRNA) or stably (shRNA and shRNA-miR),
into cells and screens can be done in arrayed (well-by-well) or
pooled formats. A disadvantage to using RNAi is its potential
for off-target effects, which can occur when RNAi sequences
bind to nontargetedmRNAs.Another limitation is that theefficacy
of mRNA knockdown varies (in unpredictable ways), depending
on the cell type and the sequence target of the RNAi molecule.
In an arrayed screen, each RNAi molecule is placed into a sin-
gle well of amicrotiter plate. The advantage to this type of screen
is that there are no confounding effects from other infected cells,
since only one knockdown or one set of knockdowns/gene are
assayed. In addition, this format is suitable for multiple types of
readouts, including colorimetric, fluorescence, and lumines-
cence assays and high-content morphological phenotyping.
The main disadvantages of array-based screens, especially
with the large number of molecules in each of these libraries,
are that costly infrastructure is required, the volume of reagents
is high, and a minimum level of automation is necessary. For
pooled approaches, the library is typically introduced into cells
en masse and, based on the statistics of infection, each cell,
on average, contains a single RNAi molecule. Following the
screen, the individual clones can be identified using barcode
microarray or sequence-based readouts (Figure 2). Pooled
approaches are more feasible for smaller laboratories, but a
disadvantage to pooled screens is that analysis of results
requires costly deconvolution through microarrays or next-gen-
eration sequencing and sufficient bioinformatic expertise to
identify the RNAi molecules that are enriched or depleted in a
pool. Our lab recently developed a microarray-based platform
that allows the deconvolution of pools of up to 90,000 shRNA
molecules (Ketela et al., 2011). The technical challenge of iden-
tifying specific molecules in highly complex RNAi libraries can
be addressed by dividing genome-scale collections into smaller
pools (Luo et al., 2009).
Chemical Genomic Screens in Mammalian Cells
Several RNAi-based genome-scale studies have been used to
study the molecular effects of DNA-damaging agents on
mammalian cells. In a proof-of-principle chemical screen, Luo
et al. (2008) performed a pool-based screen on H82 small-cell
lung cancer cells infected with 45,000 shRNAs to identify the
target of the DNA-damaging anticancer agent etoposide. As
described above, etoposide is a topoisomerase II poison and ex-
hibits increased toxicity with increased cellular levels of the topo-
isomerase II protein. This positive selection screen, which used a
high dose of etoposide, correctly identified TOPIIA as a suppres-
sor gene. Cells containing TOPIIA knockdowns exhibited up to
50-fold enrichment in etoposide treatment compared to un-
treated cells.
RNAi-based chemical screens (i.e., synthetic lethal screens)
have also been used to identify previously unknown members
in DNA damage-related pathways. In a study by Smogorzewska
et al. (2010), the Fanconi anemia-related protein FAN1 was iden-
tified in a screen for gene knockdowns that confer sensitivity to
the DNA crosslinking agent mitomycin C (MMC). U2OS cells in-
fected with a pool of 75,000 shRNAs were treated with a low
dose of MMC and analyzed for relative abundance of shRNAs656 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righcompared to an untreated control. Among the 2,173 hairpins
that conferred sensitivity to MMC, several targeted known
DDR proteins, such as BRCA1 and RAD51. The group focused
on FAN1, a previously uncharacterized protein, and found that,
in addition to conferring resistance to MMC, the protein interacts
with known mismatch repair proteins, localizes to sites of DNA
damage, and contains endo- and exonuclease activity, which in-
dicates a role in DNA repair.
In an analogous screen, HeLa cells were infected with the
same pool of 75,000 shRNAs and treated with the topoisomer-
ase I poison camptothecin (CPT) (O’Connell et al., 2010). The
screen uncovered shRNAs targeting TOP1 as enriched in CPT-
treated cells. On the opposite side, 331 hairpins were found
to confer sensitivity to CPT treatment. Among the genes with
multiple shRNAs that induce a synthetic effect, the group
discovered a protein related to yeast Mms22p/Mus7p,
MMS22L, which interacts with another hit from the screen,
NFKBIL2. An independent study also identified MMS22L and
NFKBIL2 (TONSL) in an RNAi-based screen to identify siRNAs
that lead to increased 53BP1 subnuclear foci formation in
response to ionizing radiation (O’Donnell et al., 2010). Subse-
quent experiments determined that both these proteins promote
homologous recombination repair, increase DNA damage foci
when knocked down, and accumulate at sites of replication
stress and DNA damage (O’Connell et al., 2010; O’Donnell
et al., 2010). These studies highlight the power and potential
of chemical genomic screens to identify novel genes in known
biological pathways.
Perspective
The availability of fully sequenced genomes has facilitated the
development of high-throughput technologies to systematically
probe gene function and validate drug targets to better under-
stand drugmechanism of action. This has important applications
in the development and evaluation of novel drugs to improve on
current therapeutics. In conjunction with improvements in me-
dicinal chemistry, systematic genome-wide screens provide an
effective method to evaluate structure-activity relationships,
enabling the prioritization of compounds for drug development
(Wallace et al., 2011). In addition, the identification of new ‘‘drug-
gable’’ genes that arise from genome-wide compound screens
can lead to the design of novel drugs to target these genes (Hop-
kins and Groom, 2002). Results from genomic screens can be
combined with other -omics strategies, such as proteomics
and transcriptomics, to enhance drug target discovery efforts.
Genome-wide chemical screens are designed to uncover all
genes that are important for compound response. The results
may represent genes that are important for resistance mecha-
nisms or those responsible for off-target effects of the drug.
Chemical genomic screens can be used to inform the develop-
ment of combination therapy strategies for currently used drugs.
The identification of a specific gene dosage mutant that en-
hances the function of a known compound can be used to select
drugs that mimic the gene dosage effect for combination thera-
pies. Such strategies can be used to address issues of drug
resistance and also allow for decreased individual drug dose to
circumvent adverse dose-related toxicity. In addition to their
role in drug discovery, chemical genomic screens allow the iden-
tification of compounds that can be used as chemical probes.ts reserved
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PerspectiveA goal of ours and several research groups is to enable chem-
ical genomic screens to be performeddirectly inmammalian sys-
tems. This will allow the direct study of genes and pathways that
do not have homologs in yeast. Though heterologous systems, in
which human genes are introduced to model organisms, have
been useful for studying human proteins (Outeiro and Lindquist,
2003), examining a protein’s response to drug in its native envi-
ronment would be preferable. Once a technology is established
in a ‘‘standard’’ cell line, genomic screens can be tailored to a
specific disease-relevant system. In practice, no one cell line
can be expected to model all human diseases; instead, a panel
of reference lines for each disease, complemented with patient-
derived cells, may be the most effective approach. Potential
reference systems include primary tumors, cell lines engineered
tomodel disease states, and patient-derived induced pluripotent
stem cells (iPSCs) that model specific diseases. An exciting
example of disease model to study drug function was demon-
strated in a recent study of human iPSCs generated from schizo-
phrenia patient-derived cells (Brennand et al., 2011). The iPSCs
weredifferentiated intoneurons tomodel thedisease, andsubse-
quent screening against several antipsychotic compounds
revealed that loxapine was able to reverse several schizo-
phrenia-related phenotypes in the differentiated neurons.
In addition to the application of RNAi to functional genomics in
mammalian cells, newer technologies are being developed that
enable precise genetic manipulation in human cells and should
prove scalable to the genome-wide level. One example is the
generation of human gene knockout cells using haploid human
cell lines (Carette et al., 2009). Loss-of-function chemical
screens using this technology allow the study of null alleles,
emulating screens in model organisms. Advances in genetic en-
gineering in mammalian systems include the development of
zinc finger nucleases (Carroll, 2011) and transcription acti-
vator-like effector nucleases (Christian et al., 2010). These engi-
neered nucleases can be used to target endogenous human
genes and enable site-directed insertions, deletions, and DNA
editing in human cells.
A comprehensive understanding of a drug’s mode of action is
crucial for its safe and effective use in the clinic. Chemical geno-
mics has proven to be a valuable tool to understand cellular re-
sponses to diverse compounds, including DNA-damaging
agents. The studies highlighted in this review emphasize the po-
wer of chemical genomic screens in model organisms and
mammalian systems to identify molecular targets of DNA-
damaging agents, determine the biological pathways through
which these compounds act, and further characterize the DNA
damage response pathway. The DDR pathways have important
implications in cancer development, as defects in a number of
DDR genes lead to genomic instability and are associated with
cancer predisposition; therefore, identifying genes that are
required to respond to DNA-damaging agents will allow a better
understanding of cancer biogenesis and highlight potential tar-
gets for anticancer drug development.ACKNOWLEDGMENTS
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